ANDA 204309, held by Aurobindo Pharma. Phenytoin Sodium.
As of Nov 16, 2026, ANDA 204309 (Extended Phenytoin Sodium), held by Aurobindo Pharma, was first approved by FDA on Jun 10, 2015, with 6 approved supplements and 0 published complete response letters.
Extended phenytoin sodium capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 10, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Extended Phenytoin Sodium100MG EXTENDED · capsule;oral | Phenytoin Sodium | Rx |
| Aug 3, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 3, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 3, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 3, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 3, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 3, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jun 10, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters